Edition:
United Kingdom

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

17.10USD
16 Feb 2018
Change (% chg)

$0.20 (+1.18%)
Prev Close
$16.90
Open
$16.85
Day's High
$17.23
Day's Low
$16.80
Volume
102,283
Avg. Vol
136,406
52-wk High
$18.95
52-wk Low
$11.90

Chart for

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment... (more)

Overall

Beta: 1.37
Market Cap(Mil.): $778.29
Shares Outstanding(Mil.): 44.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Vanda Pharmaceuticals Qtrly Net Loss Per Share $0.04

* VANDA PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS

14 Feb 2018

BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia

10 Nov 2017

BRIEF-Vanda Pharmaceuticals posts qtrly ‍net loss of $0.10​/share

* Qtrly ‍net loss per share $0.10​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

07 Nov 2017

BRIEF-Vanda Pharmaceuticals reached a pricing agreement with the German National Association of Statutory Health Insurance Funds

* Vanda Pharmaceuticals - On Oct 17, co reached a pricing agreement with the German National Association of Statutory Health Insurance Funds

18 Oct 2017

BRIEF-Vanda Pharmaceutical ‍announced results from study of Tradipitant as a treatment of chronic pruritus

* Vanda Pharmaceuticals Inc - ‍announced results from randomized phase ii clinical study of Tradipitant as a monotherapy in treatment of chronic pruritus

13 Sep 2017

Competitors

Earnings vs. Estimates